The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The 2022 Tandem Meetings | Barriers to enrollment in clinical trials for patients with B-NHL who progress after CAR-T therapy
Evandro Bezerra, MD, Mayo Clinic, Rochester, MN, comments on the barriers to enrollment in clinical trials for patients with aggressive B-cell non-Hodgkin lymphoma (B-NHL) who progress after CD19-directed CAR-T therapy. Approximately 60% of patients progress or relapse after treatment with CAR-T therapy and these patients have a very poor prognosis. A recent study showed that a significant proportion of these patients would be ineligible for clinical trials due to low blood counts and incomplete hematologic recovery. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
